Disease Modifying Therapies and Infection Risks in Multiple Sclerosis-a Decision-making Conundrum

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 Jul 4

PMID 32617342

Citations 4

Authors

Kok Pin Yong

Ho Jin Kim

Affiliations

Soon will be listed here.

Citing Articles

Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo.

Komoni E, Jashari F, Boshnjaku D, Myftiu B, Pushka M, Blyta A Med Sci Monit. 2024; 30:e942992.

PMID: 38287659 PMC: 10838007. DOI: 10.12659/MSM.942992.

Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study.

Zingaropoli M, Pasculli P, Iannetta M, Perri V, Tartaglia M, Crisafulli S Mult Scler J Exp Transl Clin. 2022; 8(1):20552173211065731.

PMID: 35003758 PMC: 8733376. DOI: 10.1177/20552173211065731.

Autoimmunity Increases Susceptibility to and Mortality from Sepsis.

Jensen I, Jensen S, McGonagill P, Griffith T, Mangalam A, Badovinac V Immunohorizons. 2021; 5(10):844-854.

PMID: 34702761 PMC: 9036850. DOI: 10.4049/immunohorizons.2100070.

Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia.

Al Jumah M, Abulaban A, Aggad H, Al Bunyan R, Alkhawajah M, Al Malik Y Mult Scler Relat Disord. 2021; 51:102925.

PMID: 33857897 PMC: 7992311. DOI: 10.1016/j.msard.2021.102925.

References

Barmettler S, Ong M, Farmer J, Choi H, Walter J . Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2019; 1(7):e184169. PMC: 6324375. DOI: 10.1001/jamanetworkopen.2018.4169. View

Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox R . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7):676-88. DOI: 10.1056/NEJMoa0706383. View

Ho P, Koendgen H, Campbell N, Haddock B, Richman S, Chang I . Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017; 16(11):925-933. DOI: 10.1016/S1474-4422(17)30282-X. View

Marcinno A, Marnetto F, Valentino P, Martire S, Balbo A, Drago A . Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018; 5(6):e498. PMC: 6148550. DOI: 10.1212/NXI.0000000000000498. View

Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G . Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disord. 2015; 8(5):233-8. PMC: 4622113. DOI: 10.1177/1756285615594575. View

Lau A, Qiu W, Kermode A, Au C, Ng A, Wong A . High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis. Mult Scler J Exp Transl Clin. 2018; 4(3):2055217318788699. PMC: 6050819. DOI: 10.1177/2055217318788699. View

Fox E, Buckle G, Singer B, Singh V, Boster A . Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist. Neurol Clin Pract. 2019; 9(1):53-63. PMC: 6382377. DOI: 10.1212/CPJ.0000000000000567. View

Hauser S, Bar-Or A, Comi G, Giovannoni G, Hartung H, Hemmer B . Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2016; 376(3):221-234. DOI: 10.1056/NEJMoa1601277. View

Nakahara J, Tomaske L, Kume K, Takata T, Kamada M, Deguchi K . Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?. Neurol Neuroimmunol Neuroinflamm. 2019; 6(3):e559. PMC: 6467684. DOI: 10.1212/NXI.0000000000000559. View

10.

Tintore M, Vidal-Jordana A, Sastre-Garriga J . Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2018; 15(1):53-58. DOI: 10.1038/s41582-018-0082-z. View

11.

Kim S, Kim Y, Jung J, Park N, Jang H, Hyun J . High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis. J Clin Neurol. 2019; 15(4):454-460. PMC: 6785463. DOI: 10.3988/jcn.2019.15.4.454. View

12.

Ohtani R, Mori M, Uchida T, Uzawa A, Masuda H, Liu J . Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. Mult Scler J Exp Transl Clin. 2018; 4(1):2055217318759692. PMC: 5824911. DOI: 10.1177/2055217318759692. View

13.

Berger J . Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017; 12:59-63. DOI: 10.1016/j.msard.2017.01.006. View

14.

Winkelmann A, Loebermann M, Reisinger E, Hartung H, Zettl U . Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016; 12(4):217-33. DOI: 10.1038/nrneurol.2016.21. View

15.

Wijnands J, Zhu F, Kingwell E, Fisk J, Evans C, Marrie R . Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry. 2018; 89(10):1050-1056. DOI: 10.1136/jnnp-2017-317493. View

16.

Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M . Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2019; 77(2):184-191. PMC: 6784753. DOI: 10.1001/jamaneurol.2019.3365. View

17.

Montalban X, Hauser S, Kappos L, Arnold D, Bar-Or A, Comi G . Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2016; 376(3):209-220. DOI: 10.1056/NEJMoa1606468. View

18.

Avasarala J, Jain S, Urrea-Mendoza E . Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?. J Clin Pharmacol. 2017; 57(11):1415-1418. DOI: 10.1002/jcph.945. View

19.

van Vollenhoven R, Fleischmann R, Furst D, Lacey S, Lehane P . Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol. 2015; 42(10):1761-6. DOI: 10.3899/jrheum.150051. View

20.

Farez M, Correale J, Armstrong M, Rae-Grant A, Gloss D, Donley D . Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019; 93(13):584-594. DOI: 10.1212/WNL.0000000000008157. View